Analysis of UDP-galactose 4'-epimerase mutations associated with the intermediate form of type III galactosaemia

J. S. Chhay, C. A. Vargas, T. J. McCorvie, J. L. Fridovich-Keil, D. J. Timson*

*Corresponding author for this work

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Type III galactosaemia is a hereditary disease caused by reduced activity in the Leloir pathway enzyme, UDP-galactose 4'-epimerase (GALE). Traditionally, the condition has been divided into two forms-a mild, or peripheral, form and a severe, or generalized, form. Recently it has become apparent that there are disease states which are intermediate between these two extremes. Three mutations associated with this intermediate form (S81R, T150M and P293L) were analysed for their kinetic and structural properties in vitro and their effects on galactose-sensitivity of Saccharomyces cerevisiae cells that were deleted for the yeast GALE homologue Gal10p. All three mutations result in impairment of the kinetic parameters (principally the turnover number, k(cat)) compared with the wild-type enzyme. However, the degree of impairment was mild compared with that seen with the mutation (V94M) associated with the generalized form of epimerase deficiency galactosaemia. None of the three mutations tested affected the ability of the protein to dimerize in solution or its susceptibility to limited proteolysis in vitro. Finally, in the yeast model, each of the mutated patient alleles was able to complement the galactose-sensitivity of gal10 Delta cells as fully as was the wild-type human allele. Furthermore, there was no difference from control in metabolite profile following galactose exposure for any of these strains. Thus we conclude that the subtle biochemical and metabolic abnormalities detected in patients expressing these GALE alleles likely reflect, at least in part, the reduced enzymatic activity of the encoded GALE proteins.

Original languageEnglish
Pages (from-to)108-116
Number of pages9
JournalJournal of Inherited Metabolic Disease
Volume31
Issue number1
DOIs
Publication statusPublished - Feb 2008

Fingerprint

UDPglucose 4-Epimerase
Galactosemias
Galactose
Mutation
Alleles
Yeasts
Inborn Genetic Diseases
Somatostatin-Secreting Cells
Enzymes
Proteolysis
Saccharomyces cerevisiae
Proteins
galactose epimerase

Keywords

  • EPIMERASE-DEFICIENCY GALACTOSEMIA
  • URIDINE-DIPHOSPHATE GALACTOSE-4-EPIMERASE
  • ESCHERICHIA-COLI
  • HUMAN UDP-GALACTOSE-4-EPIMERASE
  • LELOIR PATHWAY
  • ACTIVE-SITE
  • RESOLUTION
  • IDENTIFICATION
  • GALACTOKINASE
  • ENZYMES

Cite this

Chhay, J. S. ; Vargas, C. A. ; McCorvie, T. J. ; Fridovich-Keil, J. L. ; Timson, D. J. / Analysis of UDP-galactose 4'-epimerase mutations associated with the intermediate form of type III galactosaemia. In: Journal of Inherited Metabolic Disease. 2008 ; Vol. 31, No. 1. pp. 108-116.
@article{04b90f50b91b4d49a813d856375c2337,
title = "Analysis of UDP-galactose 4'-epimerase mutations associated with the intermediate form of type III galactosaemia",
abstract = "Type III galactosaemia is a hereditary disease caused by reduced activity in the Leloir pathway enzyme, UDP-galactose 4'-epimerase (GALE). Traditionally, the condition has been divided into two forms-a mild, or peripheral, form and a severe, or generalized, form. Recently it has become apparent that there are disease states which are intermediate between these two extremes. Three mutations associated with this intermediate form (S81R, T150M and P293L) were analysed for their kinetic and structural properties in vitro and their effects on galactose-sensitivity of Saccharomyces cerevisiae cells that were deleted for the yeast GALE homologue Gal10p. All three mutations result in impairment of the kinetic parameters (principally the turnover number, k(cat)) compared with the wild-type enzyme. However, the degree of impairment was mild compared with that seen with the mutation (V94M) associated with the generalized form of epimerase deficiency galactosaemia. None of the three mutations tested affected the ability of the protein to dimerize in solution or its susceptibility to limited proteolysis in vitro. Finally, in the yeast model, each of the mutated patient alleles was able to complement the galactose-sensitivity of gal10 Delta cells as fully as was the wild-type human allele. Furthermore, there was no difference from control in metabolite profile following galactose exposure for any of these strains. Thus we conclude that the subtle biochemical and metabolic abnormalities detected in patients expressing these GALE alleles likely reflect, at least in part, the reduced enzymatic activity of the encoded GALE proteins.",
keywords = "EPIMERASE-DEFICIENCY GALACTOSEMIA, URIDINE-DIPHOSPHATE GALACTOSE-4-EPIMERASE, ESCHERICHIA-COLI, HUMAN UDP-GALACTOSE-4-EPIMERASE, LELOIR PATHWAY, ACTIVE-SITE, RESOLUTION, IDENTIFICATION, GALACTOKINASE, ENZYMES",
author = "Chhay, {J. S.} and Vargas, {C. A.} and McCorvie, {T. J.} and Fridovich-Keil, {J. L.} and Timson, {D. J.}",
year = "2008",
month = "2",
doi = "10.1007/s10545-007-0790-9",
language = "English",
volume = "31",
pages = "108--116",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "1",

}

Analysis of UDP-galactose 4'-epimerase mutations associated with the intermediate form of type III galactosaemia. / Chhay, J. S.; Vargas, C. A.; McCorvie, T. J.; Fridovich-Keil, J. L.; Timson, D. J.

In: Journal of Inherited Metabolic Disease, Vol. 31, No. 1, 02.2008, p. 108-116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of UDP-galactose 4'-epimerase mutations associated with the intermediate form of type III galactosaemia

AU - Chhay, J. S.

AU - Vargas, C. A.

AU - McCorvie, T. J.

AU - Fridovich-Keil, J. L.

AU - Timson, D. J.

PY - 2008/2

Y1 - 2008/2

N2 - Type III galactosaemia is a hereditary disease caused by reduced activity in the Leloir pathway enzyme, UDP-galactose 4'-epimerase (GALE). Traditionally, the condition has been divided into two forms-a mild, or peripheral, form and a severe, or generalized, form. Recently it has become apparent that there are disease states which are intermediate between these two extremes. Three mutations associated with this intermediate form (S81R, T150M and P293L) were analysed for their kinetic and structural properties in vitro and their effects on galactose-sensitivity of Saccharomyces cerevisiae cells that were deleted for the yeast GALE homologue Gal10p. All three mutations result in impairment of the kinetic parameters (principally the turnover number, k(cat)) compared with the wild-type enzyme. However, the degree of impairment was mild compared with that seen with the mutation (V94M) associated with the generalized form of epimerase deficiency galactosaemia. None of the three mutations tested affected the ability of the protein to dimerize in solution or its susceptibility to limited proteolysis in vitro. Finally, in the yeast model, each of the mutated patient alleles was able to complement the galactose-sensitivity of gal10 Delta cells as fully as was the wild-type human allele. Furthermore, there was no difference from control in metabolite profile following galactose exposure for any of these strains. Thus we conclude that the subtle biochemical and metabolic abnormalities detected in patients expressing these GALE alleles likely reflect, at least in part, the reduced enzymatic activity of the encoded GALE proteins.

AB - Type III galactosaemia is a hereditary disease caused by reduced activity in the Leloir pathway enzyme, UDP-galactose 4'-epimerase (GALE). Traditionally, the condition has been divided into two forms-a mild, or peripheral, form and a severe, or generalized, form. Recently it has become apparent that there are disease states which are intermediate between these two extremes. Three mutations associated with this intermediate form (S81R, T150M and P293L) were analysed for their kinetic and structural properties in vitro and their effects on galactose-sensitivity of Saccharomyces cerevisiae cells that were deleted for the yeast GALE homologue Gal10p. All three mutations result in impairment of the kinetic parameters (principally the turnover number, k(cat)) compared with the wild-type enzyme. However, the degree of impairment was mild compared with that seen with the mutation (V94M) associated with the generalized form of epimerase deficiency galactosaemia. None of the three mutations tested affected the ability of the protein to dimerize in solution or its susceptibility to limited proteolysis in vitro. Finally, in the yeast model, each of the mutated patient alleles was able to complement the galactose-sensitivity of gal10 Delta cells as fully as was the wild-type human allele. Furthermore, there was no difference from control in metabolite profile following galactose exposure for any of these strains. Thus we conclude that the subtle biochemical and metabolic abnormalities detected in patients expressing these GALE alleles likely reflect, at least in part, the reduced enzymatic activity of the encoded GALE proteins.

KW - EPIMERASE-DEFICIENCY GALACTOSEMIA

KW - URIDINE-DIPHOSPHATE GALACTOSE-4-EPIMERASE

KW - ESCHERICHIA-COLI

KW - HUMAN UDP-GALACTOSE-4-EPIMERASE

KW - LELOIR PATHWAY

KW - ACTIVE-SITE

KW - RESOLUTION

KW - IDENTIFICATION

KW - GALACTOKINASE

KW - ENZYMES

UR - http://www.scopus.com/inward/record.url?scp=40849131035&partnerID=8YFLogxK

U2 - 10.1007/s10545-007-0790-9

DO - 10.1007/s10545-007-0790-9

M3 - Article

C2 - 18188677

VL - 31

SP - 108

EP - 116

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 1

ER -